Evidence map›Paper›PMID 31598599›Full record

ArticleArchives of rheumatology2019

A Multicenter Analysis of Subjectivity of Indirect Immunofluorescence Test in Antinuclear Antibody Screening.

Vildan Turan Faraşat, Talat Ecemiş, Yavuz Doğan, Aslı Gamze Şener, Gülfem Terek Ece, Pınar Erbay Dündar, Tamer Şanlidağ

Abstract read
In one paragraph

Article in Archives of rheumatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Vildan Turan FaraşatDepartment of Medical Microbiology, Manisa Celal Bayar University, Faculty of Medicine, Manisa, Turkey.
Talat EcemişDepartment of Medical Microbiology, Manisa Celal Bayar University, Faculty of Medicine, Manisa, Turkey.
Yavuz DoğanDepartment of Medical Microbiology, Dokuz Eylül University, Faculty of Medicine, Izmir, Turkey.
Aslı Gamze ŞenerDepartment of Medical Microbiology, Katip Çelebi University, Faculty of Medicine, Izmir, Turkey.
Gülfem Terek EceDepartment of Medical Microbiology, Izmir Medicalpark Hospital, Izmir, Turkey.
Pınar Erbay DündarDepartment of Public Health, Manisa Celal Bayar University, Faculty of Medicine, Manisa, Turkey.
Tamer ŞanlidağDepartment of Medical Microbiology, Manisa Celal Bayar University, Faculty of Medicine, Manisa, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: This study aims to evaluate the interpretation of the antinuclear antibody (ANA)-indirect immunofluorescence (IIF) test results based on the interpreter-related subjectivity and to examine the inter-center agreement rates with the performance of each laboratory. Patients and methods: The ANA-IIF testing was carried out in a total of 600 sera and evaluated by four laboratories. The inter-center agreement rates were detected. The same results given by the four centers were accepted as gold standard and the predictive values of each center were calculated. Results: The inter-center agreement was reported for ANA-IIF test results from 392 of 600 (65.3%) sera, while 154 of 392 results were positive. Four study centers reported 213 (35.5%), 222 (37.0%), 266 (44.3%), and 361 (60.2%) positive test results, respectively. In terms of the patterns, the highest and lowest positive predictive values were 72.3% and 42.7%, respectively, while the highest and lowest negative predictive values were 99.6% and 61.5%, respectively. The agreement for semi-quantitative evaluation at three levels of fluorescence intensity stated by four centers was detected in 100 sera at 87% 3(+), while the other two levels were 6% and 7%. The highest predictive value for the highest fluorescence intensity of 3(+) was found to be 71.9%. Conclusion: Significant differences may be observed among laboratories in terms of qualitative results, patterns, and semi-quantitative determination of the fluorescence intensity in the ANA-IIF testing, particularly at low fluorescence intensity levels and in those with speckled patterns. In case of any discrepancy between ANA-IIF test and clinical prediagnosis, the test should be repeated in another laboratory, if necessary.

Indexed as

Antinuclear antibodiesautoimmune rheumatic diseasesindirect immunofluorescencesubjectivity

Identifiers

PMID31598599
PMCPMC6768788

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.